Regenerative medtech company Isto Biologics has acquired regenerative medicine developer NovaBone Products, adding a portfolio of synthetic bioactive glass bone grafts to its orthobiologics business.
NovaBone develops synthetic bone graft products based on proprietary bioactive glass technology that are sold in more than 40 countries. The products are backed by more than 20 years of clinical evidence and are used across spine, orthopedics, foot and ankle, trauma, extremities, and dental procedures, according to an Aug. 4 news release.
The acquisition expands Isto’s portfolio of bone graft substitutes and strengthens its presence in international markets, including Europe, Asia-Pacific and Latin America. The combined company also plans to leverage complementary research, development and manufacturing capabilities to support future product innovation.
The transaction marks Isto’s first strategic acquisition and comes 10 months after Keensight Capital invested in the company. Financial terms were not disclosed.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.